SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers face failures and consolidation has intensified selling in CoreWeave and renewed concern about its debt-heavy, capital-intensive AI infrastructure model and access to financing. Traders debate whether Musk is criticizing a competitor for self-interest, while bulls point to AI demand and Nvidias backing and bears focus on borrowing costs, dilution, and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure alongside AI data-center and neocloud stocks as traders debate financing risks and Elon Musks warning that tighter credit could trigger failures among smaller operators. Bears fear debt, dilution and execution challenges, while bulls argue IRENs contracts, power access and AI partnerships distinguish it and point to continued compute demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud selloff tied to Elon Musks warning of tighter financing and consolidation among AI infrastructure providers, intensifying concerns about debt-funded expansion and data-center returns. Traders disagree on whether Nebius is vulnerable to sector-wide risks or better positioned because of its financing access and demand for AI compute.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Merck are driving discussion: traders broadly view the data as clinically promising, but the shares sold off as investors judged them against high expectations after a sharp rally. Bulls see validation for a broader cancer-vaccine platform, while bears question its commercial potential, costs and valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs REGAL Phase 3 trial of GPS for AML, with traders watching for the 80th survival event that would trigger final analysis and eventual topline results. The prolonged wait and company silence fuel debate: bulls speculate that slower event accrual reflects longer survival and possible ASH-related disclosure, while skeptics warn that the delay is uncertain and could signal problems; SLS009 data is a secondary focus.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazilian equities sold off sharply after Lulas election victory, as traders voiced concerns about policy and economic uncertainty; some alleged election irregularities without evidence. Others called the move an overreaction and viewed the drop as a buying opportunity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals steep selloff is dominating discussion, with traders citing the recent convertible offering and dilution concerns, possible hedging-related selling, and broader weakness in AI data-center stocks. Some see its contracted data-center business and expansion pipeline as long-term support, while others worry about financing, execution, and the upcoming earnings report.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

Lufaxs preliminary Q3 loss warning and planned reverse split are driving debate ahead of the full results: bearish traders see more evidence of business and shareholder risk, while some holders argue tax charges and credit provisions may distort the headline loss and are watching loan quality and originations for signs of improvement. Discussion also reflects broader weakness across Chinese fintech lenders and mistrust of management.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and steep underperformance versus Bitcoin dominate discussion, with traders focused on the lack of signed AI/data-center tenants and uncertainty around the Long Ridge deal and financing. Bears cite debt, dilution and management concerns, while bulls see an oversold setup and argue Bitcoin strength or a lease announcement could support a rebound.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL neoadjuvant colon-cancer data, including a reported 72% pathologic complete response rate in a small Phase 2 dMMR cohort, are driving attention; traders highlight the possibility of organ preservation. Optimists see promising efficacy, while skeptics question the early, limited dataset and stress the need for durable results and confirmatory Phase 3 progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 29, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM PR Newswire NEW YORK, July 29, 2026 NEW YORK, July 29, 2026 /PRNewswire...

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing of the proposed transaction, Neuphoria shareholders will own 14.5% of the combined company.Halper Sadeh encourages Neuphoria shareholders...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) PR Newswire NEW YORK, July 24, 2026 NEW YORK, July 24, 2026...

Scancell Makes Bold U.S. Push with Game-Changing Neuphoria Deal

Scancell Holdings (AIM:SCLP) and Neuphoria Therapeutics (NASDAQ:NEUP) have unveiled a transformative all-share merger designed to position the combined company for its next stage of clinical and commercial growth. Upon closing, the combined business will operate under the Scancell name and intends to list on NASDAQ under the proposed ticker SCLT, while maintaining Scancell's existing AIM listing. The transaction combines Scancell's late-stage immunotherapy pipeline with Neuphoria's public market platform and remaining cash resources, creating a company focused on advancing active cancer immunotherapies with expanded access to U.S. capital markets.

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Equity

Merck cited business reasons for the discontinuation of the investigational drug. 


NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Why Did NEUP Stock Surge 64% Today?

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.


Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.

Neuphoria Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The trial tested whether adding MK-1167, a daily capsule, to standard Alzheimer’s medicines could improve memory and thinking.</li><li>Merck ended the trial after an early planned review of the results showed the drug did not perform well enough to continue.</li><li>Merck, however, is still active in Alzheimer’s research.</li></ul>Shares of Merck &amp; Co. Inc. (MRK) fell over 2% on Wednesday after the company terminated a mid-stage study of its Alzheimer’s drug MK-1167 being developed with Neuphoria Therapeutics (NEUP), citing business reasons.The company is no longer looking for participants for the trial intended to evaluate the efficacy and safety of MK-1167 as adjunctive therapy in participants with mild to moderate Alzheimer's disease dementia, according to a post to ClinicalTrials.gov.<a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> closed the regular trading session down 19% and fell another 3% after hours.&nbsp;<h2 class="st-heading-2">What Happened With The Trial?</h2>The trial tested whether adding MK-1167, a daily capsule, to standard Alzheimer’s medicines could improve memory and thinking.Patients were randomly assigned to receive one of three doses of MK-1167 or a placebo. Neither the patients nor the researchers knew who got the real drug. The main goals were to check for improvements on a common test of thinking skills after 24 weeks and to monitor safety.The study began enrolling people in December 2024 and aimed for about 350 participants across multiple countries. It is now closed, with the last patients finishing in early June 2026.<h2 class="st-heading-2">Why Did Merck Stop It?</h2>Merck ended the trial after an early planned review of the results showed the drug did not perform well enough to continue. The company has stated that no safety concerns were identified during the trial.MK-1167 was designed to help brain cells communicate better by boosting specific signals linked to memory and attention.Merck previously also discontinued the development of another drug being developed with Neuphoria called MK-4334. The drug completed one early-stage study in 2022 that tested its effects on brain signals in healthy volunteers and people with schizophrenia. However, a planned second early-stage study in patients with Alzheimer’s disease who were already taking the drug donepezil was withdrawn before any participants were enrolled. No other compounds from the particular Merck–Neuphoria partnership have entered clinical trials.&nbsp;Merck, however, is still active in Alzheimer’s research. It continues to test another experimental drug, MK-2214, that targets a different protein in the brain. Results from that study are expected in 2029.<h2 class="st-heading-2">How Did MRK Retail Traders React?</h2>On Stocktwits, retail sentiment around MRK stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user voiced optimism for MRK stock hitting all-time highs by month-end.<stembedurl>https://www.stocktwits.com/10D_west/message/658049440</stembedurl>According to data from Koyfn, 19 of the 29 analysts covering MRK rate it ‘Buy’ or ‘Strong Buy’ while nine rate it ‘Hold’ and one rates it ‘Strong Sell.’The 12-month average price target on the stock is $130.78, representing a potential upside of over 4% from the stock’s last close.<a href="https://stocktwits.com/symbol/MRK">MRK stock</a> has gained 19% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-up-for-fourth-straight-day-of-gains-before-thursday-deliveries-report-wall-street-expects-year-on-year-growth/cZm3oddR71L">TSLA Stock Up for Fourth Straight Day Before Thursday Deliveries Report — Wall Street Expects Year-On-Year Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merck logo is displayed on a smartphone screen, with the company's green-themed branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Merck cited business reasons for the discontinuation of the investigational drug. 

Merck & Co Inc

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.44
Prev Close	$3.48
Open	$3.46
Dividend Yield	0.00%
50-Day Moving Average	$3.64
Beta	0.78
Avg. Volume	16,405.03
PE Ratio	-0.56

52-Week High	$6.01
52-Week Low	$3.19
Market Capitalization	$18.61M
EPS (Annual)	-$3.06
Price to Book	0.76
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Fundamentals

Info

NEUP Fundamentals